Opposite immune functions of GM-CSF administered as vaccine adjuvant in cancer patients.
about
Viro-immune therapy: A new strategy for treatment of pancreatic cancerAllogeneic tumor cell vaccines: the promise and limitations in clinical trialsImmunotherapy advances for glioblastomaAn update on vaccine therapy and other immunotherapeutic approaches for glioblastomaSystematic review of the use of granulocyte-macrophage colony-stimulating factor in patients with advanced melanomaThe Multifaceted Roles Neutrophils Play in the Tumor MicroenvironmentImmunotherapeutic strategies for the treatment of renal cell carcinoma: where are we now?Carbon nanotubes as vaccine scaffoldsPrevention of infection by a granulocyte-macrophage colony-stimulating factor co-expressing DNA/modified vaccinia Ankara simian immunodeficiency virus vaccineIncorporation of membrane-bound, mammalian-derived immunomodulatory proteins into influenza whole virus vaccines boosts immunogenicity and protection against lethal challengeIpilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: a randomized clinical trialCurrent status of granulocyte-macrophage colony-stimulating factor in the immunotherapy of melanoma.Effect of granulocyte/macrophage colony-stimulating factor on circulating CD8+ and CD4+ T-cell responses to a multipeptide melanoma vaccine: outcome of a multicenter randomized trialImmunogenicity and other problems associated with the use of biopharmaceuticals.Autoantibodies induced by chimeric cytokine-HIV envelope glycoprotein immunogens.CCL2 blockade augments cancer immunotherapy.Polysaccharides from dioscorea ( shān yào) and other phytochemicals enhance antitumor effects induced by DNA vaccine against melanoma.Vaccines against human carcinomas: strategies to improve antitumor immune responses.Phase II Study of Adjuvant Immunotherapy with the CSF-470 Vaccine Plus Bacillus Calmette-Guerin Plus Recombinant Human Granulocyte Macrophage-Colony Stimulating Factor vs Medium-Dose Interferon Alpha 2B in Stages IIB, IIC, and III Cutaneous MelanomaThe Chemical Characteristics and Immune-Modulating Activity of Polysaccharides Isolated from Cold-Brew CoffeeVaccination with a plasmid DNA encoding HER-2/neu together with low doses of GM-CSF and IL-2 in patients with metastatic breast carcinoma: a pilot clinical trialEffect of granulocyte/macrophage colony-stimulating factor on vaccination with an allogeneic whole-cell melanoma vaccineRole of GM-CSF signaling in cell-based tumor immunization.Overview of cellular immunotherapy for patients with glioblastoma.CD1d(hi)CD5+ B cells expanded by GM-CSF in vivo suppress experimental autoimmune myasthenia gravis.Suppressive effects on the immune response and protective immunity to a JEV DNA vaccine by co-administration of a GM-CSF-expressing plasmid in miceCo-expression of HIV-1 virus-like particles and granulocyte-macrophage colony stimulating factor by GEO-D03 DNA vaccine.Myxoma virus expressing a fusion protein of interleukin-15 (IL15) and IL15 receptor alpha has enhanced antitumor activityLower peripheral blood CD14+ monocyte frequency and higher CD34+ progenitor cell frequency are associated with HBV vaccine induced response in HIV infected individuals.Interactome analysis of myeloid-derived suppressor cells in murine models of colon and breast cancerGM-CSF is one of the main breast tumor-derived soluble factors involved in the differentiation of CD11b-Gr1- bone marrow progenitor cells into myeloid-derived suppressor cells.HSPPC-96 vaccine in metastatic melanoma patients: from the state of the art to a possible future.Oncolytic tanapoxvirus expressing FliC causes regression of human colorectal cancer xenografts in nude mice.Optimizing DC vaccination by combination with oncolytic adenovirus coexpressing IL-12 and GM-CSF.Combination immunotherapy and active-specific tumor cell vaccination augments anti-cancer immunity in a mouse model of gastric cancer.GM-CSF-induced regulatory T cells selectively inhibit anti-acetylcholine receptor-specific immune responses in experimental myasthenia gravisEffect of AcHERV-GmCSF as an Influenza Virus Vaccine AdjuvantActivation of peripheral-blood granulocytes is strongly correlated with patient outcome after immunotherapy with anti-GD2 monoclonal antibody and granulocyte-macrophage colony-stimulating factor.Encapsulated cellular implants for recombinant protein delivery and therapeutic modulation of the immune system.Monocytic CCR2(+) myeloid-derived suppressor cells promote immune escape by limiting activated CD8 T-cell infiltration into the tumor microenvironment
P2860
Q26774641-9CFBCEAB-956B-433E-A9D2-CB90D6E8F7C6Q26852333-3436D52B-7C25-48CA-B544-F4E6B3A87C16Q26866513-8DA009F7-EA7D-4717-984E-0A76291867FEQ27024830-BAEF7326-742B-42C7-B1AE-1BF2EF2FD887Q28067023-0AED822E-471C-4730-9FAD-704C151323EBQ28241308-320D1833-9701-4D56-B0BB-372291F5109AQ28301672-8E81C407-D4BF-4F47-8A05-CF2316A30A2DQ28392532-2830C08B-06FA-4F0E-94AF-B11C1D81521CQ28742137-994BAD1E-BCD6-44B5-B2DE-16C77836BB7CQ30376482-CAD9590B-1932-4BA3-A519-17A8AB56D22EQ30407940-4B2E0412-FCFE-4E36-A6BB-A4C10002F4DBQ30412300-E26FBF00-C147-4A9B-AE21-BDC71FC79425Q30434151-0EA7FB1F-6F21-40EA-80B4-C5977A56688EQ33416851-5D97ED56-0907-4021-85DA-3F1C391FFB2FQ33601372-577D43E8-40FD-46BD-ABEE-89F7CA675D23Q33651427-15783950-2B95-4AA4-A1DA-557CB97BBCA2Q33657641-7C863B09-FA93-4746-B293-C3748C02BE32Q33734281-08BA54FF-B6A4-4A74-8FD7-6EBAFB7A35B2Q33741471-CFF33146-6F10-4A44-97B7-871BADA317B3Q33888475-575696A5-AD87-4DBC-A457-CA4E946AC521Q33991804-DBA14DE0-C064-46DA-9C28-BA38FDD9500EQ34059854-229455AB-9C8B-4B6D-9831-BDD0A03A5D20Q34147010-BEF71343-2738-4FDD-B486-6BE5245080D9Q34189694-A22ECD45-E528-42BB-9AC7-F3ACF3A980D3Q34204228-158CBCC0-A80A-4DAD-A151-C45B5B45BE1CQ34228443-4CB49CBB-B81C-4F14-BB5C-4D8342F7B0E4Q34309004-D2140702-A9A0-4E72-8380-AFF3CEFDB2B7Q34351517-01D4B314-14BC-46F6-915E-AD0F96611D98Q34850890-3692E518-0F60-49BC-98AE-72B5E732E466Q34956969-066FCDA1-4753-4436-9CB0-70E003ABB3D0Q34983887-EFBDB72A-BD81-4B8B-8330-2A0235A69532Q35009889-2B503E7A-E683-4B01-A784-029B0D99E823Q35110264-F33791B5-0CA7-46B0-9280-2A98F0E02D30Q35144428-32F8A374-AE3C-4919-9DF1-5B61E25D4961Q35203752-59955285-4C3F-4C91-A456-5E6D74B1346AQ35603050-03C1F3FB-72C3-4227-A054-F60808A05146Q35668481-C90B7FC6-656F-48E5-BA7E-F233CCFE8061Q35721147-E324466D-ADDF-4B21-8712-10EB3A604446Q35723422-B7BAD0CE-56CF-4EF7-B39E-FBAAE9889A10Q35783465-E2142056-747D-4783-BA40-43DEC5E6CB19
P2860
Opposite immune functions of GM-CSF administered as vaccine adjuvant in cancer patients.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Opposite immune functions of GM-CSF administered as vaccine adjuvant in cancer patients.
@ast
Opposite immune functions of GM-CSF administered as vaccine adjuvant in cancer patients.
@en
type
label
Opposite immune functions of GM-CSF administered as vaccine adjuvant in cancer patients.
@ast
Opposite immune functions of GM-CSF administered as vaccine adjuvant in cancer patients.
@en
prefLabel
Opposite immune functions of GM-CSF administered as vaccine adjuvant in cancer patients.
@ast
Opposite immune functions of GM-CSF administered as vaccine adjuvant in cancer patients.
@en
P2093
P356
P1433
P1476
Opposite immune functions of GM-CSF administered as vaccine adjuvant in cancer patients.
@en
P2093
C Castelli
G Parmiani
L Rivoltini
M P Colombo
M Santinami
P304
P356
10.1093/ANNONC/MDL158
P577
2006-11-20T00:00:00Z